Quantcast

Latest osteosarcoma Stories

2009-11-05 13:23:33

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. While key experiments were in animals, the cancer studied closely resembled the human form and the drug has already been proven to be safe in human...

2009-10-12 14:04:00

SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring...

2009-09-23 15:06:00

A team of Israeli researchers say they have developed a new drug carrier to deliver compounds straight to a tumor to starve it of blood. Dr. Ronit Satchi-Fainaro of Tel Aviv University's Sackler School of Medicine said that like folklore's blood-sucking vampires, cancer tumors require an ample supply of blood to stay alive. Without fresh blood for sustenance, cancer cells shrivel up like raisins and die. Satchi-Fainaro and her team said the new invention that ferries a variety of existing...

2009-09-17 09:49:02

New TAU drug cuts off blood supplies to starve cancer tumors Like vampires, cancer tumors require an ample supply of blood to stay alive. Without fresh blood for sustenance, cancer cells shrivel up like raisins and die. To that end, Dr. Ronit Satchi-Fainaro of Tel Aviv University's Department of Physiology and Pharmacology, Sackler School of Medicine, and her team of researchers have developed a new drug carrier to deliver compounds straight to the tumor. Ferrying a variety of existing...

2009-09-02 07:05:00

ROCKLEIGH, N.J., Sept. 2 /PRNewswire/ -- Volvo Cars of North America (VCNA) is teaming up with Alex's Lemonade Stand Foundation (ALSF) during National Childhood Cancer Awareness Month to help families gain easier access to care and clinical trials at hospitals outside of their hometown. (Logo: http://www.newscom.com/cgi-bin/prnh/20090612/LA31208LOGO) Throughout September, donations made on Volvo's Virtual Lemonade Stand, www.lemonadestandforlife.com, will go to ALSF's Travel Fund, which...

2009-08-11 07:42:09

A new analysis suggests patients and physicians should rethink the pros and cons of limb-sparing surgery versus amputation for bone and soft tissue sarcomas of the lower limb. Patients with tumors of the bone or soft tissue in their arms and legs require surgery to remove their cancer. To compare the costs and benefits of amputation compared with limb-sparing surgery in these patients, Canadian researchers Ronald Barr, M.D., M.B., Ch.B., of McMaster University and Jay Wunder, M.D., M.Sc., of...

2009-07-23 09:44:00

INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO((R)) [teriparatide (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for...

2009-06-22 12:59:00

SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results of two related studies using Rexin-G, a tumor-targeted...

2009-06-18 10:54:01

A grant from the Liddy Shriver Sarcoma Initiative will allow Dr. Pulivarthi Rao, associate professor of pediatrics at Baylor College of Medicine, and his team of researchers to explore the role of the gene CDC5L in the development of osteosarcoma, the most common bone cancer in children. Rao received the $50,000 one-year grant for his research proposal, "Molecular basis of genomic instability in osteosarcoma." "Osteosarcoma is often present with complex chromosomal rearrangements, deletions...

2009-05-18 12:17:00

SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related